Key result
Circulating C-reactive protein levels serve as a marker of cardiovascular risk and may contribute to the underlying mechanisms of human atherosclerosis.
This review highlights the role of CRP not just as an inflammatory marker, but as an active contributor to atherosclerosis and a valuable predictor of cardiovascular risk.
Answers are grounded in this paper and cite their sources.
CRP aids risk stratification but should not alter practice; leaves open causal role and therapeutic targeting in atherosclerosis.
C-reactive protein (CRP) is the first acute phase protein that has been described in the literature. It is phylogenetically ancient and - with serum amyloid P - belongs to proteins named as "pentraxin". After being considered a marker of acute inflammation for several decades and fruitfully used in clinical practice, CRP has been recently considered as a potential contributor to inflammatory diseases including atherosclerosis as well as a marker of cardiovascular risk. With regard to the first topic, inflammation is now believed to represent the underlying mechanism leading to the formation of human atheroma and favouring both the destabilization of vulnerable plaques and the formation of occlusive thrombi. In this regard, numerous studies indicated that modest changes in circulating CRP levels, as detected by highly sensitive methods, can be extremely useful in predicting cardiovascular and perhaps cerebrovascular diseases in apparently healthy individuals as well as in patients affected by atherosclerosis. Subjects manifesting with identical low density cholesterol and/or blood pressure levels have different rates of cardiovascular accidents on the basis of different circulating CRP concentrations. In addition, women with identical cardiovascular risk profiles developed more type 2 diabetes in the presence of higher circulating CRP levels and thereby are expected to display divergent cardiovascular prognosis. Therefore, even slight changes in circulating CRP concentrations - assuming that blood is collected appropriately and CRP is measured with correct methods - could help clinicians in defining individual cardiovascular risk. In this review, we have firstly described the current understanding of the structure of CRP, its function, and interaction with the vascular endothelial cell. Then, we have discussed how to measure circulating CRP and the more recent findings on the suggested role of circulating CRP as a novel cardiovascular risk factor.
No takes yet. Share an insight, caveat, or question.
Ferri et al. (2007) conducted a review in Atherosclerosis and cardiovascular risk. C-Reactive Protein (CRP) was evaluated. Circulating C-reactive protein levels serve as a marker of cardiovascular risk and may contribute to the underlying mechanisms of human atherosclerosis.
Synapse has enriched 10 related papers. Consider them for comparative context: